Session Abstract – PMWC 2022 Silicon Valley


  • Hope or Hype? The Role of ML in Drug Discovery and Development (PANEL)
    Session Chair: Ansuman Satpathy, Stanford University
    - Marcel Hop, Genentech
    - Noam Solomon, ImmunAI
    - Stacie Calad-Thomson, BioSymetrics
  • Advancing Research and Drug Discovery with UK Biobank
    Session Chair: Asha Collins, DNAnexus
    - Mark Effingham, UK Biobank
  • AI in Small Molecule Design and Screening
    Session Chair: Alex Zhavoronkov, Insilico Medicine
    - Najat Khan, Johnson & Johnson
    - Martin Emanuel Bittner, Arctoris
  • AI/ML in Clinical Trial Design, Patient Selection and Prediction of Outcomes
    Session Chair: Peter Lipsky, Ampel Bio
    - Mika Newton, xCures, Inc.
    - Mark Smith, MedStar Health
    - William Oh, Sema4
  • Emerging Data-driven Clinical Trials
    Session Chair: Adrian Lee, UPMC
    - Laura Esserman, UCSF
    - Derek Angus, UPMC
  • Generating Novel Insights through AI and Multimodal Analysis
    - Philippe Menu, SOPHiA GENETICS
  • Pfize's Data and Analytics Efforts
    - Susie Stephens, Pfizer
  • PMWC 2022 Showcase
    - Kevin Cho, Envisagenics, Inc.
    - Poojitha Ojamies, Novartis

 Session Chair Profile

M.D., Ph.D., Assistant Professor, Stanford University

Biography
Dr. Ansuman Satpathy M.D., Ph.D. in the Department of Pathology at Stanford University School of Medicine. He is a member of the Stanford Cancer Institute, the Parker Institute for Cancer Immunotherapy, the Immunology, Cancer Biology, and Biomedical Informatics Programs, Bio-X, and a faculty fellow in ChEM-H. Dr. Satpathy completed an M.D. and Ph.D. in immunology at Washington University in St. Louis, clinical residency in pathology at Stanford Hospital and Clinics, and postdoctoral training in genetics at Stanford University. Dr. Satpathy’s research group focuses on developing and applying genome-scale technologies to study fundamental properties of the immune system in health, infection, and cancer.


 Session Chair Profile

Ph.D., Founder and CEO, Insilico Medicine Inc.

Biography
Alex Zhavoronkov, PhD, is the founder&CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and insurance industry. Since 2015 he has invented critical technologies in the field of GANs and reinforcement learning for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. He has published over 130 peer-reviewed research papers and 2 books. He serves on the editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and co-chairs the Annual Aging Research,Drug Discovery, and AI Forum.


 Session Chair Profile

M.D., CEO, CMO, AMPEL BioSolutions

Biography
Peter is a Rheumatologist & Immunologist who immerses himself in basic & clinical research. He received his medical degree from the New York University School of Medicine, completed residency training at the Strong Memorial Hospital in Rochester, New York and his post-doctoral fellowship in NIAID at the NIH. After going to UT Southwestern Medical Center at Dallas, Peter rapidly advanced to become a professor of Internal Medicine and Microbiology as well as the Director of the Harold C Simmons Arthritis Research Center and, Co-Director of the Immunology Graduate Program. He entered the new millennium as the Director of the Intramural Research Program & the Autoimmunity Branch of NIAMS at the NIH. Peter is the co-founder and CEO of AMPEL BioSolutions LLC, a biotech company involved in employing analysis of BigData and Machine Learning to provide personalized medicine. Peter is the former editor of the Journal of Immunology, Nature Reviews Rheumatology and Arthritis Research & Therapy, and is the recipient of the Carol Nachman Prize, the American College of Rheumatology Distinguished Investigator Award and the Arthritis Foundation’s Lee Howley prize.

Talk
AI/ML in Clinical Trials


 Session Chair Profile

M.D., Ph.D., SVP, Chief Medical Officer, SOPHiA GENETICS

Biography
Dr. Philippe Menu, MD, PhD, MBA, brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology and business management consulting. He joined SOPHiA GENETICS in 2020 from McKinsey & Company, where he had spent the last 8 years serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases. Philippe obtained his MD and PhD from the University of Lausanne, and his MBA in life sciences from the Open University Business School.

Talk
Generating Novel Insights through AI and Multimodal Analysis
Thanks to new technologies and computing capacities, multimodality holds the potential to increase precision in diagnosis, prognosis and treatment decisions. Dr. Menu will apply this to a large-scale multi-centric study where the deep-learnings analysis of the aggregation of multimodal data (clinical, biological, genomic, and radiomics data) is used to identify predictive signatures associated with response to treatment and prognosis of patients with stage IV non-small cell lung cancer.


 Session Chair Profile

Ph.D., Professor and Director, Institute for Precision Medicine, University of Pittsburgh and UPMC

Biography
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalized well-being and clinical care. He is also Professor of Pharmacology & Chemical Biology and Human Genetics at UPMC Hillman Cancer Center. Dr. Lee received B.Sc. and Ph.D. degrees in England, and came to San Antonio, Texas for his postdoctoral studies. He was subsequently recruited to Baylor College of Medicine and to the University of Pittsburgh in 2010. The goal of Dr. Lee’s research laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. Dr Lee has published over 180 peer reviewed research articles. His laboratory is supported by funding from the NIH, Department of Defense, Susan G. Komen for the Cure, Breast Cancer Research Foundation, and other sources.


 Speaker Profile

Ph.D., Vice President, Genentech Inc.

Biography
Cornelis E.C.A. “Marcel” Hop is Vice-President at Genentech and supervising the DMPK department. He leads a team of about 85 scientists involved in acquisition and interpretation of ADME data in support of drug discovery and development ranging from early stage research to NDA and beyond. Before that, he was a Senior Director at Pfizer and a Senior Research Fellow at Merck and he received his Ph.D. from the University of Utrecht (The Netherlands). He has extensive experience in ADME sciences with a particular focus on PK optimization, human PK prediction, biotransformation, bioanalysis and the use of in silico approaches in drug discovery.


 Speaker Profile

Ph.D., Chief Strategy Officer and Head of Drug Discovery, BioSymetrics

Biography
Stacie is a pharmaceutical R&D and biotech leader with expertise in AI and machine learning applications for drug discovery. At BioSymetrics she guides the company on its drug discovery and partnering strategies, with a focus on translating human-relevant disease biology. Prior to BioSymetrics, Stacie led collaborations and partnerships in the AI-powered drug discovery space as Vice President and Head of AI Molecular Screening Partnerships at Atomwise. Previously she established and co-led the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, a public-private partnership developing machine learning tools to accelerate drug discovery. She worked at GSK for more than 13 years, starting as a process chemist and moving up into R&D strategy and operations roles where she led several change initiatives and teams. Stacie holds a B.S. in Chemistry from University of California Berkeley and a Ph.D. in chemistry from University of California Irvine.


 Speaker Profile

Ph.D., Chief Data Science Officer and Global Head, Janssen R&D Strategy and Operations, Johnson & Johnson

Biography
Najat Khan, PhD, is the Chief Data Science Officer and the Global Head of Strategy & Operations for Janssen Research & Development. In these roles Dr Khan leads a team of 100+ data scientists and data engineers to drive deep impact across Janssen’s pipeline and portfolio and shapes Janssen’s R&D strategy, spanning key pipeline and portfolio decisions to new strategic initiatives to deliver on transformational medicines for patients. Dr Khan co-chairs the Johnson & Johnson Data Science Council and is a member of Janssen’s Development and Investment Committees. Dr Khan was a Senior Principal at The Boston Consulting Group and received her Ph.D. in Organic Chemistry from the University of Pennsylvania and her B.A. in Chemistry with a minor in Economics from Colgate University.


 Speaker Profile

CEO, xCures Inc.

Biography
Mika has more than 20 years of commercial strategy and leadership experience in life sciences, with a focus on novel technologies. Over the last 10 years, Mika has concentrated on evidence-based medicine and tools to transform healthcare and clinical development. Before joining xCures Mika was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.


 Speaker Profile

M.D., Director, UCSF Breast Care Center, UCSF

Biography
Dr. Esserman's work spans the spectrum from basic science to public policy issues, and the impact of both on the delivery of clinical care. She is recognized as a thought leader in cancer screening and over-diagnosis, as well as innovative clinical trial design. She led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes. The Athena Network launched the PCORI-funded Wisdom Study, which tests a personalized approach to breast cancer screening in 100,000 women. She is also a leader of the innovative I-SPY TRIAL model, designed to accelerate the identification and approval of effective new agents for women with high risk breast cancers. In 2020 she got FDA approval for an I-SPY Covid trial, designed to rapidly screen and confirm high impact treatments to reduce mortality and time on ventilators.


 Speaker Profile

M.D., M.P.H, Chief Innovation Officer and Executive Vice President, UPMC

Biography
Dr. Angus oversees UPMC's clinical research, implementation science and data analytics, with a particular emphasis on UPMC's learning health system initiatives. He also is associate vice chancellor for Healthcare Innovation at the University of Pittsburgh Schools of the Health Sciences. He is a distinguished professor and holds the Mitchell P. Fink Endowed Chair in Critical Care Medicine at the University of Pittsburgh, with secondary appointments in Medicine, Health Policy and Management, and Clinical and Translational Science. Since 2008, Dr. Angus has served as chair of the Department of Critical Care Medicine. Since 2015, he also has been the physician director of the UPMC ICU Service Center, responsible for the provision of ICU services across the 30-plus hospital system. He also is a senior editor at JAMA.


 Speaker Profile

Director, Business Development, Envisagenics

Biography
Kevin leads the business development efforts to form research collaboration partnerships with biopharma companies. Over the years, Kevin has worked in small-to-midsize biotechs and CROs gathering a wide spectrum of experience in pre- and post-IND development. With his previous role at Integrium, he has helped kickstart an investment arm leading equity and bridge financing investments with micro-cap and small-cap public biopharma companies.


 Speaker Profile

Ph.D., Product Director, data42, Novartis

Biography
Dr. Ojamies currently serves as Product Director for data42, Novartis - a transformational R&D program to leverage 2 million patient-years of data in one of the largest and most diverse datasets in the pharma industry, with the ultimate moonshot goal to change the way we develop medicines. Dr. Ojamies leads the strategy and development of user-facing products aimed at providing greater access to clinical & RWE data as well as collaborative product solutions for improved patient stratification, safety, and trial optimization thereby reimagining the drug discovery and development process. She brings in extensive experience from the life sciences, technology, and startup world to develop product solutions in drug research and development. Dr. Ojamies obtained her Ph.D. in Clinical Hematology and Oncology from the University of Helsinki and went on to work with BenevolentAI and Novartis. She has contributed significantly in the space of product development leveraging big data and AI for drug discovery.


 Speaker Profile

M.D., Founding & Former Chief Innovation Officer, MedStar Health

Biography
Mark Smith is an emergency medicine physician who for the past 11 years has led a broad initiative to catalyze innovation in a large not-for-profit healthcare system, helping build centers in simulation training, human factors in healthcare, and telehealth innovation. He was co-creator of the Azyxxi/Amalga clinical information system which was in continuous use in hospitals for 22 years. Dr. Smith’s interests include digital health, advanced computational tools, complex systems theory, information visualization, disaster medicine, catalyzing sustainable and self-organizing change, and scaling that change within and across large systems of care. Prior to his appointment as director of the MedStar Institute for Innovation, Dr. Smith served as chair of the department of emergency medicine at MedStar Washington Hospital Center, Georgetown University School of Medicine, and at The George Washington University Hospital. He is a graduate of Swarthmore College (mathematics), Stanford University (computer science), and Yale University (medicine).


 Speaker Profile

Ph.D., CEO, Immunai

Biography
Noam is the CEO and Co-Founder at immunai, the first and only company to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, immunai has mapped out thousands of immune cells and their functions, building the largest proprietary data set in the world for clinical immunological data. Prior to co-founding immunai, Noam had a dual career in both the industry and academia. Noam is a double PhD, and served as a post-doctoral researcher in the Mathematics department at MIT, and in the center of mathematical sciences and applications at Harvard University. In his research, he developed and applied tools from algebra and Algebraic Geometry in the study of classical problems in combinatorics. Noam also worked as an algorithms developer in the Israeli defense forces and subsequently as a data scientist, consultant and head of data science in several hi-tech companies in Israel.


 Speaker Profile

M.D., DPHIL, CEO, Arctoris Ltd

Biography
Martin-Immanuel Bittner is the CEO of Arctoris, the drug discovery platform company that he co-founded in Oxford in 2016. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including EACR, AACR, and ESTRO. In recognition of his research achievements, he was elected a member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.


 Speaker Profile

M.D., Chief Medical Science Officer, Sema4; Clinical Professor of Medicine, Tisch Cancer Inst., Mount Sinai

Biography
William K. Oh, M.D. is Chief Medical Science Officer at Sema4, a patient-centered health intelligence company focused on precision medicine. He is also an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. He continues to see cancer patients in his capacity as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai. William has authored more than 330 articles, reviews, books and book chapters related to genitourinary cancers. He has conducted multiple clinical cancer trials and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association.